Showing results (411-420 of 424) with videos related to
Sort By:
Pageof 43
Computational and Structural Biotechnology Journal|April 11, 2025
HELENA project: Driving innovation in high energy density Li-metal halide solid-state batteries for electric vehicles and aircraftsPedro López-Aranguren, Pierre Lannelongue, Javier Carrasco, et al.Cellular and Molecular Gastroenterology and Hepatology|December 15, 2022
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal TransitionGiulia Rizzo, Federica Rubbino, Sudharshan Elangovan, et al.Ophthalmology and Therapy|November 4, 2023
Knowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA NetworkCarla Gaggiano, Vishali Gupta, Rupesh Agrawal, et al.Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.Biorxiv : the Preprint Server for Biology|May 7, 2026
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate CancerJie Luo, Jianzhang Yang, Jean Ching-Yi Tien, et al.Journal of Medicinal Chemistry|February 23, 2022
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of ActionRamulu Poddutoori, Kimberly Aardalen, Kiran Aithal, et al.Nature Communications|August 31, 2019
Maximizing binary interactome mapping with a minimal number of assaysSoon Gang Choi, Julien Olivet, Patricia Cassonnet, et al.Nature|May 3, 2023
Glioblastoma remodelling of human neural circuits decreases survivalSaritha Krishna, Abrar Choudhury, Michael B Keough, et al.Proceedings of the National Academy of Sciences of the United States of America|July 7, 2026
A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancerXiaoju Wang, Wenyan Liu, Jiehao Yang, et al.Journal of Medicinal Chemistry|April 27, 2012
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitorsMark A Ashwell, Jean-Marc Lapierre, Christopher Brassard, et al.Pageof 43